Osteoporosis Treatments Affect Bone Matrix Maturation in a Rat Model of Induced Cortical Remodeling.

Excerpt

The example of sodium fluoride (NaF) clearly demonstrates an instance where increasing bone mass while altering maturation can negatively affect drug efficacy. NaF was a promising osteoporosis treatment because it increased BMD.⁵ However, it became evident that the treated patients were at increased risk of fracture,^{6, 7} which was later attributed to NaF-induced aberrant mineralization.⁸ Had there been a preclinical model to assess the effect of NaF on maturation, it is likely that these fractures could have been avoided.

References

• 5. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Eng J Med. 1990;322(12):802–9.

  Crossref CAS PubMed Web of Science®Google Scholar

• 6. Schnitzler CM, Wing JR, Gear KA, Robson HJ. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res. 1990;261:268–75.

  PubMed Web of Science®Google Scholar

• 7. Hedlund LR, Gallagher JC. Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res. 1989;4(2):223–5.

  Wiley Online Library CAS PubMed Web of Science®Google Scholar

• 8. Fratzl P, Roschger P, Eschberger J, Abendroth B, Klaushofer K. Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray-scattering study. J Bone Miner Res. 1994;9(10):1541–9.

  Wiley Online Library CAS PubMed Web of Science®Google Scholar

*Full study online at https://asbmr.onlinelibrary.wiley.com/doi/full/10.1002/jbm4.10344